Search results for "Colore"

showing 10 items of 1250 documents

FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial

2018

Abstract Aim of the study The optimal therapeutic strategy in patients with rectal cancer and synchronous unresectable metastases remains unknown. We evaluated the efficacy of FOLFIRINOX induction therapy in this setting. Patients and methods Chemotherapy-naive patients received at least 8 cycles of FOLFIRINOX. The primary end-point was the 4-month disease control (4 m DC) rate. Tumour responses were centrally reviewed and assessed by computed tomography scan for metastases (Response Evaluation Criteria in Solid Tumours criteria) and magnetic resonance imaging for rectal tumorus. With a Simon 2-stage design and a targeted (H1) 4 m DC > 75%, 65 patients were enrolled from July 2012 to Februa…

MaleCancer ResearchLung NeoplasmsColorectal cancerFOLFIRINOXGastrointestinal DiseasesSynchronous metastasesLeucovorinKaplan-Meier EstimateInduction0302 clinical medicineInduction therapyAntineoplastic Combined Chemotherapy ProtocolsRectal cancerINDUCTION TREATMENTFatigueResponse rate (survey)medicine.diagnostic_testLiver NeoplasmsRemission InductionMiddle AgedCombined Modality TherapyMagnetic Resonance ImagingProgression-Free Survival3. Good healthOxaliplatinFOLFIRINOXTreatment OutcomeOncology030220 oncology & carcinogenesis030211 gastroenterology & hepatologyFemaleRadiologyFluorouracilAdultmedicine.medical_specialty[SDV.CAN]Life Sciences [q-bio]/CancerAdenocarcinomaIrinotecan03 medical and health sciencesmedicineHumansParesthesiaAgedPerformance statusbusiness.industryRectal NeoplasmsMagnetic resonance imagingmedicine.diseaseHematologic DiseasesConfidence intervalLocal controlbusinessTomography X-Ray ComputedFollow-Up Studies
researchProduct

Influence of sample return time and ambient temperature on the performance of an immunochemical faecal occult blood test with a new buffer for colore…

2016

IF 2.415; International audience; The haemoglobin concentration measured by faecal immunochemical tests (FIT) may be decreased in cases of delayed sample return or high temperature. It is an issue of great importance. The aim of this study was to investigate the effects of sample return time and of season on the performance of an FIT (FOB-Gold) with a new buffer. The study included 20 371 participants involved in the French organized colorectal cancer (CRC) screening programme. The probability of a positive screening test, detection rates and positive predictive values for CRC and advanced adenoma were analysed according to sample return time and season of screening. A sample of positive FI…

MaleCancer ResearchMultivariate analysisTime FactorsEpidemiologyColorectal cancerMESH: Reagent Kits DiagnosticMESH : AgedMESH : HemoglobinsMESH : Early Detection of Cancer[ SDV.CAN ] Life Sciences [q-bio]/CancerReturn timeScreening programmeImmunoenzyme TechniquesHemoglobinsMESH : Specimen HandlingMESH : FemaleMESH : Neoplasm StagingMESH : Reagent Kits DiagnosticMESH : TemperatureEarly Detection of CancerMESH: AgedMESH: Middle AgedMESH : PrognosisTemperatureMESH: Follow-Up StudiesMESH: Neoplasm StagingMiddle AgedPrognosisPredictive valueMESH: TemperatureMESH: HemoglobinsMESH : Occult BloodOncologyColorectal cancer screeningOccult BloodFemaleSeasonsMESH : Colorectal NeoplasmsColorectal NeoplasmsMESH : Time FactorsAdenomamedicine.medical_specialtySample (material)MESH : Male[SDV.CAN]Life Sciences [q-bio]/CancerMESH: PrognosisSpecimen HandlingAnimal scienceMESH : Immunoenzyme TechniquesmedicineHumansMESH: Early Detection of CancerMESH : Middle AgedMESH: Specimen HandlingMESH: Immunoenzyme TechniquesAgedNeoplasm StagingMESH: AdenomaMESH: HumansMESH : Seasonsbusiness.industryMESH: Time FactorsMESH : HumansPublic Health Environmental and Occupational HealthMESH : Follow-Up Studiesmedicine.diseaseMESH: MaleSurgeryMESH : AdenomaReagent Kits DiagnosticFaecal occult blood testbusinessMESH: Occult BloodMESH: FemaleMESH: SeasonsMESH: Colorectal NeoplasmsFollow-Up Studies
researchProduct

Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer

2017

Background: Limited data exist regarding the correlation between MRI tumour regression grade (mrTRG) and pathological TRG (pTRG) in rectal cancer. Methods: mrTRG and pTRG were compared in rectal cancer patients from two phase II trials (EXPERT and EXPERT-C). The agreement between radiologist and pathologist was assessed with the weighted κ test while the Kaplan–Meier method was used to estimate survival outcomes. Results: One hundred ninety-one patients were included. Median time from completion of neoadjuvant treatment to pre-operative MRI and surgery was 4.1 weeks (interquartile range (IQR): 3.7–4.7) and 6.6 weeks (IQR: 5.9–7.6), respectively. Fair agreement was found between mrTRG and pT…

MaleCancer ResearchPathologySURGERYColorectal cancerACCURACYmedicine.medical_treatmentMagnetic resonance tumour regression gradePREOPERATIVE CHEMORADIATIONKaplan-Meier EstimateTHERAPY030218 nuclear medicine & medical imaging0302 clinical medicineInterquartile rangeRectal cancerNeoadjuvant therapyAged 80 and overCOMPLETE RESPONSEmedicine.diagnostic_testMiddle AgedMagnetic Resonance ImagingNeoadjuvant TherapyOncology030220 oncology & carcinogenesisFemaleRadiologyLife Sciences & BiomedicineRADIOTHERAPYAdultmedicine.medical_specialtyCytodiagnosismagnetic resonance tumour regression gradeDisease-Free Survival03 medical and health sciencesClinical Trials Phase II as TopicmedicinePathological tumour regression gradeHumansOncology & Carcinogenesisrectal cancerPathologicalpathological tumour regression gradeAgedNeoplasm StagingScience & TechnologyRectal Neoplasmsbusiness.industryTOTAL MESORECTAL EXCISIONMagnetic resonance imagingChemoradiotherapy AdjuvantRANDOMIZED PHASE-IIINEOADJUVANT CHEMORADIOTHERAPYmedicine.diseaseClinical trialRadiation therapyClinical StudyFOLLOW-UPbusiness1112 Oncology And CarcinogenesisChemoradiotherapy
researchProduct

POLE, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genes

2021

POLE, POLD1, and NTHL1 are involved in DNA replication and have recently been recognized as hereditary cancer-predisposing genes, because their alterations are associated with colorectal cancer and other tumors. POLE/POLD1-associated syndrome shows an autosomal dominant inheritance, whereas NTHL1-associated syndrome follows an autosomal recessive pattern. Although the prevalence of germline monoallelic POLE/POLD1 and biallelic NTHL1 pathogenic variants is low, they determine different phenotypes with a broad tumor spectrum overlapping that of other hereditary conditions like Lynch Syndrome or Familial Adenomatous Polyposis. Endometrial and breast cancers, and probably ovarian and brain tumo…

MaleCancer ResearchSettore MED/06 - Oncologia MedicaColorectal cancerBiologymedicine.disease_causeGermlineFamilial adenomatous polyposisDeoxyribonuclease (Pyrimidine Dimer)Breast cancerNeoplasmsGeneticsmedicineHumansGenetic Predisposition to DiseasePoly-ADP-Ribose Binding ProteinsMolecular BiologyDNA Polymerase IIIGenetic testingMutationPOLD1medicine.diagnostic_testDNA Polymerase IIDNAmedicine.diseaseLynch syndromePOLE POLD1 and NTHL1Lynch SyndromeCancer researchFemaleOncogene
researchProduct

Effect of self-regulatory behaviour change techniques and predictors of physical activity maintenance in cancer survivors: a 12-month follow-up of th…

2021

Abstract Background Current knowledge about the promotion of long-term physical activity (PA) maintenance in cancer survivors is limited. The aims of this study were to 1) determine the effect of self-regulatory BCTs on long-term PA maintenance, and 2) identify predictors of long-term PA maintenance in cancer survivors 12 months after participating in a six-month exercise intervention during cancer treatment. Methods In a multicentre study with a 2 × 2 factorial design, the Phys-Can RCT, 577 participants with curable breast, colorectal or prostate cancer and starting their cancer treatment, were randomized to high intensity exercise with or without self-regulatory behaviour change technique…

MaleCancer ResearchTime FactorsCancer survivorsLogistic regressionBody Mass Indexlaw.inventionTobacco UseProstate cancerRandomized controlled trialBehavior TherapylawOdds RatioMedicineRC254-282DeterminantsHigh intensityNeoplasms. Tumors. Oncology. Including cancer and carcinogensBehaviour changeMiddle AgedBehavioural supportEndurance TrainingVDP::Medisinske Fag: 700::Helsefag: 800OncologySelf-regulationRegression AnalysisFemaleColorectal NeoplasmsMonth follow upmedicine.medical_specialtyBehaviour changeMaintenancePhysical activityBreast NeoplasmsSelf-ControlConfidence IntervalsGeneticsHumansExerciseSwedenMotivationCancer och onkologibusiness.industryResearchProstatic NeoplasmsCancerResistance Trainingmedicine.diseaseActigraphyCancer and OncologyQuality of LifePhysical therapybusinessFollow-Up StudiesBMC Cancer
researchProduct

Sequential boost in neoadjuvant irradiation for T3N0-1 rectal cancer: long-term results from a single-center experience.

2016

Purpose To evaluate the influence of radiation dose on tumor regression grade (TRG) and sphincter preservation rate in a series of cT3N0-1 rectal cancer patients treated with neoadjuvant chemoradiotherapy (CT-RT) with or without a sequential radiation boost. Materials and methods Between May 2002 and September 2013, 116 cases were eligible for retrospective evaluation. Radiotherapy was delivered for a total dose of 45 Gy (no boost arm) or 50.4 Gy (boost arm). TRG was evaluated with the Dworak scale. Results Median follow-up was 62 months (range, 12-138 months). The 5-year overall survival and local control rates were 72% and 93%, respectively. Fifty-five patients (47%) were treated with a s…

MaleCancer ResearchTime FactorsTumor downsizingColorectal cancermedicine.medical_treatmentAnal CanalKaplan-Meier EstimateSingle Center030218 nuclear medicine & medical imaging0302 clinical medicineAdjuvantNeoadjuvant therapyDigestive System Surgical ProceduresTumor Regression GradeIleostomyMedicine (all)Colorectal cancer; Radiation therapy; Tumor downsizing; Adenocarcinoma; Adult; Aged; Anal Canal; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Digestive System Surgical Procedures; Female; Fluorouracil; Follow-Up Studies; Gastrointestinal Tract; Humans; Ileostomy; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organ Sparing Treatments; Radiotherapy Dosage; Radiotherapy Adjuvant; Rectal Neoplasms; Retrospective Studies; Time Factors; Treatment Outcome; Urogenital System; Medicine (all); Oncology; Cancer ResearchRadiotherapy DosageGeneral MedicineChemoradiotherapyMiddle AgedNeoadjuvant TherapyRadiation therapyTreatment OutcomeOncology030220 oncology & carcinogenesisFemaleRadiologyFluorouracilmedicine.drugAdultmedicine.medical_specialtyUrogenital SystemAntineoplastic AgentsAdenocarcinomaCapecitabine03 medical and health sciencesmedicineHumansCapecitabineAgedNeoplasm StagingRetrospective StudiesRadiotherapybusiness.industryRectal Neoplasmsmedicine.diseaseColorectal cancerRadiation therapyGastrointestinal TractConcomitantRadiotherapy AdjuvantbusinessOrgan Sparing TreatmentsChemoradiotherapyFollow-Up StudiesTumori
researchProduct

Reduced expression of Hugl-1, the human homologue of Drosophila tumour suppressor gene lgl, contributes to progression of colorectal cancer.

2005

The human gene, human giant larvae (Hugl-1/Llg1/Lgl1) has significant homology to the Drosophila tumour suppressor gene lethal(2)giant larvae (lgl). The lgl gene codes for a cortical cytoskeleton protein, Lgl, that binds Myosin II and is involved in maintaining cell polarity and epithelial integrity. The human protein, Hugl-1 contains several conserved functional domains found in Lgl, suggesting that these proteins may have closely related functions. Whether loss of Hugl expression plays a role in human tumorigenesis has so far not been extensively investigated. Thus, we evaluated tumour tissues from 94 patients undergoing surgery for colorectal cancer (CRC) for loss of Hugl-1 transcription…

MaleCancer ResearchTranscription Geneticmedicine.disease_causeCell MovementNeoplasmsGene expressionDrosophila ProteinsIntestinal MucosaCytoskeletonReverse Transcriptase Polymerase Chain ReactionCell CycleCell migrationCell DifferentiationMiddle AgedImmunohistochemistryGene Expression Regulation NeoplasticDrosophila melanogasterDisease ProgressionFemaleColorectal NeoplasmsAdenomaAdultTumor suppressor geneBlotting WesternGreen Fluorescent ProteinsDown-RegulationBiologyCell LineDownregulation and upregulationCell Line TumorGeneticsmedicineCell AdhesionAnimalsHumansCell adhesionMolecular BiologyGeneTumor Suppressor ProteinsCarcinomaProteinsProtein Structure TertiaryCytoskeletal ProteinsMicroscopy FluorescenceTumor progressionImmunologyCancer researchCaco-2 CellsCarcinogenesisOncogene
researchProduct

Quantitative fluorescence determination of long-fragment DNA in stool as a marker for the early detection of colorectal cancer

2008

Background: A variety of molecular markers have been evaluated for the development of a non-invasive approach to the diagnosis of colorectal cancer. We aimed to validate the diagnostic accuracy, using the same threshold as in the previous pilot study, of fluorescent long DNA test as a relatively simple and inexpensive tool for colorectal cancer detection.Methods: A case-control study was conducted on 100 healthy subjects and 100 patients at first diagnosis of colorectal cancer. Human long-fragment DNA in stool was quantified by fluorescence primers and a standard curve and expressed in DNA nanograms.Results: We validated the 25-ng value, which emerged as the most accurate cut-off in the pil…

MaleCancer ResearchdiagnosisAdenomatous Polyposis Coli Proteinlong-fragment DNAcolorectal cancercolorectal cancerlcsh:RC254-282Polymerase Chain ReactionPathology and Forensic MedicineFecesFluorescence long DNABiomarkers TumorHumanslcsh:QH573-671stoolEarly Detection of CancerAgedDNA PrimersFluorescent DyesAged 80 and overlcsh:CytologyCell BiologyGeneral MedicineDNAMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensCase-Control StudiesMolecular MedicineFemaleOtherTumor Suppressor Protein p53Colorectal Neoplasms
researchProduct

Familial aggregation of tumors and detection of hereditary non-polyposis colorectal cancer in 3-year experience of 2 population-based colorectal-canc…

1995

The clinical data of 2 population-based registries, located in areas with different incidence rates of colorectal cancer, were used in order to assess the role of familial factors in the pathogenesis of these tumors. The occurrence of tumors in family members was investigated in 389 subjects with colorectal cancer registered in Modena (Northern Italy, an area characterized by a high incidence of colorectal malignancies) between 1984 and 1986; similar information was obtained in 213 patients with tumors of the large bowel registered in Ragusa (Sicily, Southern Italy, an area of similar magnitude and with low incidence rates for these tumors) in the 3-year period 1988 to 1990. In both series,…

MaleCancer Researchmedicine.medical_specialtyColorectal cancerPopulationRisk FactorsInternal medicineEpidemiologyPrevalenceMedicineHumansRegistriesRisk factoreducationAgedFamily Healtheducation.field_of_studybusiness.industryIncidence (epidemiology)IncidenceCancerFamily aggregationmedicine.diseaseColorectal Neoplasms Hereditary NonpolyposisLynch syndromeSurgerynot availableOncologyItalyEvaluation Studies as TopicCase-Control StudiesFemalebusinessColorectal NeoplasmsInternational journal of cancer
researchProduct

Impact of screening programme using the faecal immunochemical test on stage of colorectal cancer: Results from the IMPATTO study

2019

To evaluate the impact of faecal immunochemical test (FIT) screening on stage distribution at diagnosis, and to estimate relative incidence rates by stage in screened at first and subsequent rounds vs. unscreened. We included all incident cases occurring in 2000-2008 in 50- to 71-year-olds residing in areas with an FIT-screening programme. Multinomial logistic models were computed to estimate the relative risk ratio (RRR) of stages I and IV, compared to stage II + III, adjusting for age, sex, geographical area, and incidence year. Proportions were then used to estimate incidence rate ratios (IRR) by stage for screened subjects at the first and at subsequent rounds vs. unscreened subjects, a…

MaleCancer Researchmedicine.medical_specialtyColorectal cancerPrevalenceSocio-culturaleColonoscopyColorectal NeoplasmSettore MED/42 - Igiene Generale E Applicatacolorectal cancer screeningScreening programmeFeces03 medical and health sciences0302 clinical medicinecolonoscopyFaecal immunochemical test colonoscopy colorectal cancer screening epidemiology cancer registriesInternal medicineEpidemiologymedicineHumansStage (cooking)Early Detection of CancerAgedNeoplasm StagingProportional Hazards Modelscancer registriemedicine.diagnostic_testFaecal immunochemical testbusiness.industryIncidence (epidemiology)IncidenceMiddle Agedmedicine.diseaseImmunohistochemistryOncologyItalycancer registries030220 oncology & carcinogenesisRelative riskOccult BloodepidemiologyFeceFemaleNeoplasm GradingColorectal NeoplasmsbusinessHuman
researchProduct